



February 18, 2026

Participation in the Research and Development Project Led by Institute of Science Tokyo, Selected for AMED "Project Focused on Developing Key Technology for Discovering and Manufacturing Drugs for Next-Generation Treatment and Diagnosis (Drug Development Using Next-generation Drug-Delivery System)" (2nd Open Call)

– Advancing non-clinical development and manufacturing of active-targeting heteroduplex oligonucleotide therapeutics toward the clinical application –

Rena Therapeutics Inc.

Rena Therapeutics Inc. (Headquarters: Chiyoda-ku, Tokyo; President & CEO: Shuichi Toriya) is pleased to announce its participation as a collaborating institution in a research and development project proposed and led by Institute of Science Tokyo (Principal Investigator: Kotaro Yoshioka, Specially Appointed Lecturer).

This project has been selected by the Japan Agency for Medical Research and Development (AMED) for the FY2025 "Project Focused on Developing Key Technology for Discovering and Manufacturing Drugs for Next-Generation Treatment and Diagnosis (Drug Development Using Next-generation Drug-Delivery System)" (2nd Open Call).

■ Overview of the Selected Project

- **Program Name:** Project Focused on Developing Key Technology for Discovering and Manufacturing Drugs for Next-Generation Treatment and Diagnosis (Drug Development Using Next-generation Drug-Delivery System)
- **Research and Development Project Title:** Preclinical development of active-targeting type Heteroduplex oligonucleotide therapeutics toward clinical advancement
- **Principal Investigator:** Kotaro Yoshioka, Specially Appointed Lecturer, Institute of Science Tokyo

■ Our Role in this R&D Project

In collaboration with Institute of Science Tokyo, we will be responsible for advancing non-clinical studies, which is a crucial phase toward the practical application of "active-targeting heteroduplex oligonucleotide (HDO) therapeutics". Specifically, we will contribute to the clinical advancement of these innovative oligonucleotide therapeutics by providing (synthesizing) the active-targeting ligands that are key to this technology, manufacturing the active pharmaceutical ingredient (API) for Good Laboratory Practice (GLP) studies of the development candidate, establishing a supply system, and conducting studies to confirm their potential.

[About Rena Therapeutics Inc.]

- **Established:** January 2015
(Joined the Nippon Shokubai Group in November 2019)
- **Capital:** 100 million yen
- **Representative:** Shuichi Toriya, President & CEO
- **Location:** 1-9-2 Otemachi, Chiyoda-ku, Tokyo
- **Business:** Providing platform technologies for oligonucleotide therapeutics drug discovery
- **Website:** <https://www.renatherapeutics.com/>

[Contact Information for Inquiries]

Rena Therapeutics Inc.

Hisayo Miyagawa

General Manager, Business Development

Phone: +81-3-4243-6081

Email: info@renatherapeutics.com